- Home
- XERS vs DNTH Comparison
XERS vs DNTH Comparison
Compare XERS & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XERS
- DNTH
- Stock Information
- Founded
- XERS 2005
- DNTH 2015
- Country
- XERS United States
- DNTH United States
- Employees
- XERS N/A
- DNTH N/A
- Industry
- XERS Biotechnology: Pharmaceutical Preparations
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- XERS Health Care
- DNTH Health Care
- Exchange
- XERS Nasdaq
- DNTH Nasdaq
- Market Cap
- XERS 628.7M
- DNTH 657.0M
- IPO Year
- XERS 2018
- DNTH N/A
- Fundamental
- Price
- XERS $5.07
- DNTH $17.31
- Analyst Decision
- XERS Strong Buy
- DNTH Strong Buy
- Analyst Count
- XERS 6
- DNTH 8
- Target Price
- XERS $6.25
- DNTH $53.00
- AVG Volume (30 Days)
- XERS 2.1M
- DNTH 255.5K
- Earning Date
- XERS 05-08-2025
- DNTH 05-12-2025
- Dividend Yield
- XERS N/A
- DNTH N/A
- EPS Growth
- XERS N/A
- DNTH N/A
- EPS
- XERS N/A
- DNTH N/A
- Revenue
- XERS $222,551,000.00
- DNTH $6,524,000.00
- Revenue This Year
- XERS $33.96
- DNTH N/A
- Revenue Next Year
- XERS $19.87
- DNTH N/A
- P/E Ratio
- XERS N/A
- DNTH N/A
- Revenue Growth
- XERS 29.88
- DNTH 102.36
- 52 Week Low
- XERS $2.03
- DNTH $13.37
- 52 Week High
- XERS $6.07
- DNTH $32.27
- Technical
- Relative Strength Index (RSI)
- XERS 54.35
- DNTH 37.87
- Support Level
- XERS $4.71
- DNTH $16.91
- Resistance Level
- XERS $5.09
- DNTH $18.45
- Average True Range (ATR)
- XERS 0.22
- DNTH 1.12
- MACD
- XERS -0.00
- DNTH -0.20
- Stochastic Oscillator
- XERS 58.93
- DNTH 19.57
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.